These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25109421)

  • 21. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
    Suh GH; Greenspan AJ; Choi SK
    Int J Geriatr Psychiatry; 2006 Jul; 21(7):654-60. PubMed ID: 16821257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010.
    Okumura Y; Togo T; Fujita J
    Int Psychogeriatr; 2015 Mar; 27(3):407-15. PubMed ID: 25213318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
    Weiser M; Rotmensch HH; Korczyn AD; Hartman R; Cicin-Sain A; Anand R;
    Int J Geriatr Psychiatry; 2002 Apr; 17(4):343-6. PubMed ID: 11994888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Don't use antipsychotics routinely to treat agitation and aggression in people with dementia.
    Corbett A; Burns A; Ballard C
    BMJ; 2014 Nov; 349():g6420. PubMed ID: 25368388
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
    Franco KN; Messinger-Rapport B
    J Am Med Dir Assoc; 2006 Mar; 7(3):201-2. PubMed ID: 16503315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
    Kurz A; Schwalen S S; Schmitt A
    Int Psychogeriatr; 2005 Dec; 17(4):605-16. PubMed ID: 16185378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.
    Herrmann N; Rabheru K; Wang J; Binder C
    Am J Geriatr Psychiatry; 2005 Jun; 13(6):527-34. PubMed ID: 15956273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of neuropsychiatric symptoms in patients with dementia.
    Yaffe K
    N Engl J Med; 2007 Oct; 357(14):1441-3. PubMed ID: 17914047
    [No Abstract]   [Full Text] [Related]  

  • 30. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
    Aarsland D; Hutchinson M; Larsen JP
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dementia.
    Warner J; Butler R; Arya P
    Clin Evid; 2004 Jun; (11):1250-77. PubMed ID: 15652059
    [No Abstract]   [Full Text] [Related]  

  • 33. Risperidone for Psychosis-Induced Aggression or Agitation.
    Scruth E
    Issues Ment Health Nurs; 2019 Nov; 40(11):988-989. PubMed ID: 31381459
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances.
    Suh GH; Son HG; Ju YS; Jcho KH; Yeon BK; Shin YM; Kee BS; Choi SK
    Am J Geriatr Psychiatry; 2004; 12(5):509-16. PubMed ID: 15353389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discontinuation of risperidone in Alzheimer's disease.
    Ling SM; Bonner AF; McMullen TL
    N Engl J Med; 2013 Jan; 368(2):187. PubMed ID: 23301740
    [No Abstract]   [Full Text] [Related]  

  • 36. Discontinuation of risperidone in Alzheimer's disease.
    Power GA
    N Engl J Med; 2013 Jan; 368(2):186-7. PubMed ID: 23301739
    [No Abstract]   [Full Text] [Related]  

  • 37. Discontinuation of risperidone in Alzheimer's disease.
    Gnjidic D; Hilmer SN
    N Engl J Med; 2013 Jan; 368(2):186. PubMed ID: 23301738
    [No Abstract]   [Full Text] [Related]  

  • 38. Discontinuation of risperidone in Alzheimer's disease.
    Devanand DP; Schultz SK; Sultzer DL
    N Engl J Med; 2013 Jan; 368(2):187-8. PubMed ID: 23301737
    [No Abstract]   [Full Text] [Related]  

  • 39. Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.
    Wang D; Noda Y; Zhou Y; Nitta A; Furukawa H; Nabeshima T
    Neuropharmacology; 2007 Sep; 53(3):379-89. PubMed ID: 17632185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?
    Norén U; Björner A; Sonesson O; Eriksson L
    Schizophr Res; 2006 Jul; 85(1-3):302-4. PubMed ID: 16675200
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.